Company intelligence / Profile preview

GenBioPro

Las Vegas, Nevada, United States

Ownership: Private
Development stage: Other

Overview

GenBioPro markets and sells FDA-approved generic mifepristone and misoprostol for medical abortion; the drugs are established as safe, effective (97% success rate), and are available across the United States. GenBioPro controls about two-thirds of the U.S. mifepristone market and is the leading generic supplier, having distributed approximately 850,000 units nationwide since its approval in 2019. The company is engaged in active legal defense and advocacy to maintain access in a changing regulatory landscape.[2][3][4][6][7]

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on GenBioPro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenBioPro.

Explore the full profile